CathWorks

The question an image can't answer: how much does the narrowing really matter?

A doctor looking at an image of a coronary artery can see that a narrowing exists, and roughly how narrow it is. What the doctor cannot see is whether that narrowing actually limits blood flow to the heart. These are two different questions: the first is about geometry, the second is about function. It is well known that judging by eye from the image does not predict the answer to the second question well.

This distinction is not academic. It decides whether the patient will have a catheterization with a stent implanted or be treated with medication only: an invasive procedure versus conservative treatment, with completely different costs and risks.

The index designed to answer the functional question has existed for years, but it is used far less than the guidelines recommend. The reason is not that it doesn't work, but that it is cumbersome: it requires an extra procedure within the procedure. And when a test is recommended but cumbersome, it simply doesn't get done, and the decision goes back to relying on how things look to the eye. This is the gap the company was built to close.

FFRangio: a functional index from an angiogram that was already taken

The standard measurement, fractional flow reserve (FFR), is done by inserting a thin pressure wire into the artery. The wire measures the pressure at a single point beyond the narrowing, while a drug is given that widens the blood vessels to simulate exertion. This is an invasive procedure in its own right: extra time, extra equipment, an extra drug and extra risk, however small.

The CathWorks system does it differently. It takes the angiography images already taken in the catheterization lab, reconstructs a 3D model of the arterial tree from them, and calculates an equivalent functional index on that model. Medtronic describes the technology as "drug-free, wire-free."

There is also a difference in the scope of the measurement, not only in convenience. A pressure wire measures at the point where it was inserted; the calculation gives a functional assessment of the whole arterial tree at once. For the doctor, this changes the question: not "is this narrowing significant?" but "where in the whole system is there a problem?"

ALL-RISE: the trial that put the index to the test

A technology that replaces a physical measurement with a computational estimate must prove that the estimate is good enough. The trial designed for this is called ALL-RISE: a randomized controlled trial that included more than 1,900 patients at 59 medical centers in North America, Asia, Europe and the Middle East. The first-year results were presented at the American College of Cardiology conference in 2026.

The result: FFRangio was found to be non-inferior to pressure-wire measurement in terms of serious cardiac events within one year, along with better use of resources and a shorter procedure.

It is worth understanding what "non-inferior" means, because the word misleads many readers. It is not a claim that the new method is better. It is a more measured claim: that it is not worse to a clinically meaningful degree. In a case like this, that is exactly the result you want. If the medical outcome is the same, the advantage comes from the procedure being shorter, simpler and cheaper, and so it will actually be done in many more cases.

FDA clearance, and what exactly it covers

The database of the US Food and Drug Administration records the first clearance for the FFRangio system under number K182149. The application was submitted in August 2018, and the decision, "Substantially Equivalent," was issued on 19 December 2018. A further clearance was granted in December 2019.

The category the device was classified under is telling in itself: "Angiographic Coronary Vascular Physiologic Simulation Software." In other words, the regulator treats it as software that simulates and estimates, not as a device that measures directly. This is a distinction the user must keep in mind.

The 510(k) pathway does not confirm that the device benefits the patient; it establishes that it is similar enough to an existing approved device to be sold. The clinical proof comes from studies such as ALL-RISE, separately. And as with any support tool of this kind, the treatment decision, whether to perform a catheterization or not, stays with the doctor. As of today, the system is marketed in the United States, Europe and Japan.

The Medtronic deal, step by step

The business path here was gradual and well documented, and it is worth reading in order. In 2022 a strategic collaboration was signed with Medtronic. It included a co-promotion agreement for the FFRangio system in the United States, Europe and Japan, and a commitment to invest up to $75 million in the company.

In February 2026 Medtronic announced its intention to acquire the company in full. Some reports described the announcement as the exercise of a purchase option set in advance in that same agreement. The acquisition was completed on 20 April 2026.

The exact figure matters, because this is where frequent mistakes happen. According to Medtronic's announcement, the deal is valued at $585 million, plus performance-based follow-on payments whose size was not disclosed. Some of the press coverage described the $585 million as the total ceiling of the deal, rather than as a base with additional payments on top. "Not disclosed" does not mean "unlimited": any total figure that appears alongside the deal is an outside estimate, not a figure the buyer provided. This is one of the largest deals made in Israel in AI-based medical technology.

What the acquisition teaches about the medical device industry

Deals like this one show the common path for an Israeli medical AI company: not an independent public offering, but an acquisition by a large device corporation that is already in the catheterization lab and can distribute the product through its existing sales channels.

The logic is simple from both directions. For the corporation, the algorithm adds value to equipment it already sells and strengthens the system around it. For the startup, it is the fast way to reach hospitals it has no chance of entering alone. That is not because of the product's quality, but because of long purchasing cycles, local approvals and trust built over years.

There is also a price. From the moment of the acquisition, the pace of development and the priorities are set by the buyer, and a process that moves fast in a startup can slow down inside a large organization. In this case, the sale was preceded by a four-year collaboration that let both sides test each other before they committed, a pattern that has become more and more common in the industry.